NO CALL ON RECORD
the engine publishes a call only when every gate clears
SEE THE LEDGER →FINNENCE ▪ THE ASSET FILE
PERMANENT ASSET RECORD · TRACKED BY FINNENCE
NVO
Novo Nordisk
$39.40
LAST CLOSE2026-09-22 · -1.0%Novo Nordisk — 12 stories tracked over the last 30 days. No call on record.
LAST $39.40·Δ1D -1.0%·Δ20D -16.0%·60D RANGE $39.40–$50.96·FROM 60D HIGH -22.7%·RADAR FLAGS 30D 12
SECTION 01 · THE MACHINE'S FILE
WHAT FINNENCE THINKS.
NO OPEN PAPER POSITION
the $1K paper fund holds nothing here
VIEW THE PAPER FUND →NOT A MEMBER OF ANY TRACKED THEME
theme membership updates every few hours
ALL THEMES →RADAR FLAG · Sep 23, 2026
CORRELATION BREAK
SEVERITY 1.2 · Z -0.4 · -16.0%
COMPANY CATALYST
Novo CEO signals M&A opportunities to strengthen drug pipeline - CNBC
ON THE RADAR →SECTION 02 · THE PRICE RECORD
NINETY SESSIONS, ONE LINE.
LAST$39.40Δ1D-1.0%Δ20D-16.0%60D RANGE$39.40–$50.96
INTERACTIVE PRICE — TRADINGVIEW
INTERACTIVE CHART — LOADS WHEN VISIBLE
SECTION 03 · THE STORY FLOW
WHAT THE FEED SAW.
Recent stories2026-09-22 08:53 UTCNEWSUNCLEARNovo CEO signals M&A opportunities to strengthen drug pipeline - CNBC
2026-09-22 08:53 UTCNEWSMIXEDNovo defends diversification push as CEO eyes deals beyond obesity - CNBC
2026-09-21 17:14 UTCNEWSBULLISHEli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
2026-09-21 12:00 UTCCOMPANYUNCLEARNew Phase 3 trial: A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A — Novo Nordisk A/S
2026-09-21 08:31 UTCNEWSBEARISHNovo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
2026-09-17 14:31 UTCNEWSUNCLEARParoxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
2026-09-17 07:05 UTCNEWSUNCLEARClarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
2026-09-16 21:37 UTCNEWSBULLISHNovo Nordisk and Anthropic will work together to speed up drug development using artificial intelligence, per Bloomberg.
2026-09-14 07:00 UTCNEWSMIXEDNovo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
SECTION 04 · CATALYSTS
2027-01-25 12:00 UTCTRIALA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabe
2027-01-29 12:00 UTCTRIALARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
LATEST PRICES
NO PRICE SAMPLES.
METHODOLOGY · PAPER ONLY
OPEN THE MACHINE →A permanent, data-backed asset record. Calls are immutable; market data and machine detections update. PAPER ONLY · NOT FINANCIAL ADVICE.
INSPECT THE PAPER FUND →